Preventing tuberculosis with bacillus Calmette-Guérin vaccine: a meta-analysis of the literature.
about
Intranasal vaccination with messenger RNA as a new approach in gene therapy: use against tuberculosisA second-generation anti TB vaccine is long overdueAntibodies and tuberculosisOral delivery of Mycobacterium bovis BCG in a lipid formulation induces resistance to pulmonary tuberculosis in miceIdentification of Mycobacterium tuberculosis counterimmune (cim) mutants in immunodeficient mice by differential screeningInduction of IDO by bacille Calmette-Guérin is responsible for development of murine depressive-like behaviorNovel genome polymorphisms in BCG vaccine strains and impact on efficacy.The Phytochemical Bergenin Enhances T Helper 1 Responses and Anti-Mycobacterial Immunity by Activating the MAP Kinase Pathway in MacrophagesCost-effectiveness of novel vaccines for tuberculosis control: a decision analysis study.Highly persistent and effective prime/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based tuberculosis vaccine with interleukin-15 as a molecular adjuvant.Pulmonary immunization using antigen 85-B polymeric microparticles to boost tuberculosis immunity.Influence of Mycobacterium bovis bacillus Calmette Guérin on in vitro induction of CD1 molecules in human adherent mononuclear cellsInoculation of Bacillus Calmette-Guerin to mice induces an acute episode of sickness behavior followed by chronic depressive-like behavior.Tuberculin skin-test reactions are unaffected by the severity of hyperendemic intestinal helminth infections and co-infections.Early secreted antigen ESAT-6 of Mycobacterium tuberculosis promotes protective T helper 17 cell responses in a toll-like receptor-2-dependent manner.The role of environmental factors in modulating immune responses in early lifeInfluence of advanced age on Mycobacterium bovis BCG vaccination in guinea pigs aerogenically infected with Mycobacterium tuberculosisProtection against Mycobacterium leprae infection by the ID83/GLA-SE and ID93/GLA-SE vaccines developed for tuberculosis.A century of tuberculosis.Mycobacterium bovis BCG substrains confer different levels of protection against Mycobacterium tuberculosis infection in a BALB/c model of progressive pulmonary tuberculosis.Molecular confirmation of Bacillus Calmette Guerin vaccine related adverse events among Saudi Arabian children.Immunogenicity of recombinant Mycobacterium bovis bacille Calmette-Guèrin clones expressing T and B cell epitopes of Mycobacterium tuberculosis antigens.Molecular immunity to mycobacteria: knowledge from the mutation and phenotype spectrum analysis of Mendelian susceptibility to mycobacterial diseases.Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis.A screen to identify small molecule inhibitors of protein-protein interactions in mycobacteria.ESAT-6 and HspX improve the effectiveness of BCG to induce human dendritic cells-dependent Th1 and NK cells activation.Genetic diversity and dynamic distribution of Mycobacterium tuberculosis isolates causing pulmonary and extrapulmonary tuberculosis in ThailandHuman CD8+ T cells from TB pleurisy respond to four immunodominant epitopes in Mtb CFP10 restricted by HLA-B alleles.Mycobacterium tuberculosis culture filtrate protein 10-specific effector/memory CD4⁺ and CD8⁺ T cells in tubercular pleural fluid, with biased usage of T cell receptor Vβ chains.Bridging implementation, knowledge, and ambition gaps to eliminate tuberculosis in the United States and globallyKnowledge gaining by human genetic studies on tuberculosis susceptibility.The influence of BCG vaccine strain on mycobacteria-specific and non-specific immune responses in a prospective cohort of infants in UgandaThe importance of animal models in tuberculosis vaccine development.Protective capacity of proteoliposomes from Mycobacterium bovis BCG in a mouse model of tuberculosisManagement and outcome of Bacille Calmette-Guérin vaccine adverse reactions.Lactoferrin enhanced efficacy of the BCG vaccine to generate host protective responses against challenge with virulent Mycobacterium tuberculosisGenomic expression catalogue of a global collection of BCG vaccine strains show evidence for highly diverged metabolic and cell-wall adaptations.Goats primed with Mycobacterium bovis BCG and boosted with a recombinant adenovirus expressing Ag85A show enhanced protection against tuberculosis.The success and failure of BCG - implications for a novel tuberculosis vaccine.Single intranasal mucosal Mycobacterium bovis BCG vaccination confers improved protection compared to subcutaneous vaccination against pulmonary tuberculosis.
P2860
Q21256673-19289C88-EEEC-43C9-8CB2-01120057AB9EQ24800887-8B54ED35-0574-4799-9F56-026A10EF8031Q28067735-563618E4-E170-49C1-9181-ED3DA7A924F9Q28218674-1B1DD44D-48E2-4ACE-A80A-0CC0531E9E2BQ28486518-CEA28062-B331-46FF-9E86-DA166CCF8357Q28508390-8F030CBA-5BBD-41AB-8A49-E605C6465C77Q33369563-3F9DB985-9D8B-4EEE-B086-25B310D93627Q33619303-000AEF2C-9EDA-436C-84C7-8F51E3A65F14Q33804506-F249F99B-FD55-43A5-94C2-7B35A5EFC387Q33825708-BDE968D1-1178-4F71-92F6-5F69051D4B62Q33954601-56E7BA09-8603-46DF-B703-8AAA8EE20BC0Q34009687-61EEB89A-4BB6-4887-B95C-D821895CC59BQ34012783-C58F0E05-831C-4894-97A1-0A8A4ED796E8Q34024833-9D78B6B3-1836-4F12-925A-25B449E03DCBQ34079170-D544A45E-ABAB-4BC7-974B-3AD0F5335F60Q34169396-643D0DBB-96FD-46AB-A310-F96A49077DC2Q34190011-0FDDDF7C-D120-47BA-AE77-AD3B525D9710Q34298351-7701B08C-006A-47EA-BDB8-1221A69EDF5AQ34322814-6FE9B65A-C4CC-4F67-B751-C81F4382CC7AQ34491796-241FC87C-E8EF-455A-B59C-79E9F7130241Q34542530-D2B5A19E-2EE3-4A49-A04D-ADE7B358EA6AQ34607605-3E1D0784-4CF4-4971-A81B-1F218E4C0C10Q34809934-2CF69271-D6ED-4473-BC5E-09D40EEC8A91Q34975770-F0E47741-7788-4BBE-A717-E11C5CA3C718Q35007917-41B9E740-E536-4AA3-88DC-2055AFF9EFAFQ35018368-2A73F0D8-72FC-4B9D-ACF6-3D028C031453Q35036241-BC743ED9-76A9-4374-9C1B-C063349EC37FQ35070059-0C113B88-77DE-4D8D-B499-4FC819A6F257Q35139260-76CD98C7-C710-4AD0-A85E-2EFCE275AD13Q35193579-C17502AD-490F-4AB9-BCED-20E4DA20130EQ35202903-757A4802-3C85-45AD-BC8C-DFA0B66E4CABQ35859543-2FC97DF5-791B-4B89-B52C-0BE83E3D6F44Q35895817-EACCD2E1-EF88-4B8C-A17D-7C2C3EB1EE54Q35896225-72BEC87D-CF5F-4224-BED6-70D08ABDB0A2Q36092315-1FE85932-4B03-4274-8A2B-526C5B7015B2Q36143523-03040D44-B016-47CE-BC35-B373F7CD9728Q36187495-CBBFE08E-4754-49C5-B5B8-3D30137F62D4Q36191665-8CB31A29-319B-498E-8BEB-1BFB544F1B78Q36191944-09EB851E-C23D-41D1-B808-79F05DA7F152Q36229158-FDDA24DA-493B-4A3C-85C2-2C705FB266E2
P2860
Preventing tuberculosis with bacillus Calmette-Guérin vaccine: a meta-analysis of the literature.
description
2000 nî lūn-bûn
@nan
2000 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Preventing tuberculosis with b ...... ta-analysis of the literature.
@ast
Preventing tuberculosis with b ...... ta-analysis of the literature.
@en
Preventing tuberculosis with b ...... ta-analysis of the literature.
@nl
type
label
Preventing tuberculosis with b ...... ta-analysis of the literature.
@ast
Preventing tuberculosis with b ...... ta-analysis of the literature.
@en
Preventing tuberculosis with b ...... ta-analysis of the literature.
@nl
prefLabel
Preventing tuberculosis with b ...... ta-analysis of the literature.
@ast
Preventing tuberculosis with b ...... ta-analysis of the literature.
@en
Preventing tuberculosis with b ...... ta-analysis of the literature.
@nl
P2860
P356
P1476
Preventing tuberculosis with b ...... ta-analysis of the literature.
@en
P2093
P2860
P356
10.1086/314072
P407
P478
31 Suppl 3
P577
2000-09-01T00:00:00Z